Browse by category

Researchers from Northwestern Medicine at Northwestern University, Chicago, Ill, have discovered novel molecular mechanisms that contribute to recovery from diabetic kidney disease following bariatric surgery in adolescents with type 2 diabetes and obesity. These mechanisms may serve as potential targets for non-surgical treatments for diabetic kidney disease, according to a multi-institutional study co-authored by Dr Thomas Inge, the Lydia J Fredrickson Board Designated Prof

Marginal ulcers (MU) occurred at a relatively high rate after Roux-en-Y gastric bypass (RYGB) compared with one-anastomosis gastric bypass (OAGB), according to a study by researchers from the Kasr Alainy Medical School, Cairo University, Cairo, Egypt. They noted that type 2 diabetes mellitus (T2DM) and the RYGB procedure were significant predictors of MU after adjusting for the confounding factors. The authors noted that despite the success of RYGB, MU has been recognised as

GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, according to a large register-based study carried out in collaboration between the University of Eastern Finland, Karolinska Institutet in Stockholm and Griffith University in Australia. Infographic on anxiety and depression in the UK (Credit: Mark Taylor) "An earlier study examining Swedish registers found the use of GLP-

In a recent position statement, the International Federation for the Surgery and Other Therapies for Obesity (IFSO) has ‘cautiously’ supported the selective use of ring augmentation (ra) in both primary and revisional metabolic bariatric surgery (MBS), particularly for Roux-en-Y Gastric Bypass (raRYGB). The findings were reported in the paper, ‘Ring-augmented Metabolic Bariatric Surgery Procedures GRADE based International Federation for the Surgery of Obesity and Metabolic

A research team affiliated with National Institute of Standards and Technology has made a significant discovery explaining why liver cancers associated with obesity and metabolic disorders tend to be more aggressive and less responsive to conventional treatments. The study reveals that a specific signalling pathway involving endotrophin - a protein secreted during liver fibrosis - and the receptor protein CD44 promotes tumour malignancy and drug resistance. Led by Professor J

By integrating genetic findings from several of the world's largest biobanks, investigators from Mass General Brigham built metabolic a polygenic risk score (PRS) for predicting obesity and type 2 diabetes (T2D), which capture multiple genetic risk factors to provide an estimate for whether a person may develop a complex medical condition and how they might fare long-term, and outperformed existing disease-prediction models and predicted downstream morbidity and clinical inte